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Abstract 
Purpose 
The purpose of this study was to compare inflammatory events and graft 
characteristics one and 6 months after conjunctival limbal autograft (CLAU) with 
and without intraoperative mitomycin C (MMC). 
Methods 
This study included 69 eyes of 69 patient’s eyes with pterygium. Clinical data 
concerning patient demography; preoperative examination including pterygium 
morphology, recurrence clinical assessment, and complications after CLAU with 
(MMC+) and without ( MMC-) intraoperative MMC were all registered at 1 and 6 
months after surgery.  
Results 
Thirty-five eyes were included in MMC+ and 34 in MMC-. Preoperative data 
were similar in both groups (Student t test and Fisher’s exact test;; p<0.05).  
Thirty four (49.6 %) eyes in the whole sample showed at least one inflammatory 
complication at 1 month after surgery. MMC- group showed a significantly 
higher number of cases with complications (p <0.001; Chi2 test). (MMC+ 
28.5%; MMC-70.5%).No patients presented clinical recurrence at 1 month after 
surgery. The examination revealed a higher incidence of clinical hyperemia 
surrounding the surgical site and graft contraction on the host site on the MMC- 
group, both with statistical signification (p <0.001; Chi2 test).  Although the 
hemorrhages were less frequent in the MMC– group there were no significant 
differences between the two groups (p >0.05; Chi2 test). Pyogenic granuloma 
developed at the surgical site in 3 eyes (4.37%), 2 of those granulomas were at 
the  MMC– group (p>0.05). 
Tendency for recurrences was significantly different between both groups 
(p=0.0001; Fisher’s exact test) at the end of 6 months. Thirteen (38%) eyes 
showed recurrence in MMC- and no cases were displayed in MMC+. Presence 
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of at least 1 inflammatory event was only seen in 16 (23%) cases, all of them in 
MMC-. Specifically, 15 (44%) eyes showed hyperemia and one (3%) eye 
presented conjunctival hemorrhages. No new cases of pyogenic granuloma or 
graft contraction were seen at this time point in both groups. Hyperemia was the 
only specific event with significant differences between MMC- and MMC+ (p= 
0.0001; Fisher’s exact test) at 6 months after surgery. 
Conclusion 
The eyes receiving intraoperative MMC after CLAU seems to present less 
hyperemia and graft contraction after surgery than those that did not receive 
MMC as an adjuvant factor. Intraoperative MMC could be associated with a 
lower recurrence rates. 
 
Introduction 
 Pterygium is a pathological progressive growth of fibrovascular 
conjunctival tissue from bulbar conjunctiva towards the center of the cornea. 
Although initially, it was described as a chronic degenerative disease1, 
histopathological findings like proliferative cells in its head and the presence of 
different inflammatory markers found in its tissue2 have recently changed this 
concept towards the proliferative and inflammatory nature of the lesion.2 
 Many adjuvant treatments associated with pterygium surgery have been 
established over the past years in order to reduce recurrences, like the 
application of cytostatics such as mitomycin C (MMC)3 and 5-fluorouracil4, the 
application of amniotic membrane5,6 and conjunctival or conjunctival limbal 
autograft (CLAU) placement7. Recently, it has been demonstrated that adjuvant 
combination in the same surgery procedure yields a lower recurrence rate. 
Indeed, the combination of conjunctival or limbal autograft with MMC reduces 
more the recurrence rate than the same treatment without MMC application.8  
Chan et al9, recently demonstrated that conjunctival autograft (CAU) and 
intraoperative MMC are a safe option when used together in pterygium surgery. 
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Although in this study, CAU seems to have lower long-term recurrence rate 
compared to MMC over bare sclera in double-head pterygium surgery.  
 MMC is an alkylating antitumor antibiotic isolated from Streptomyces 
caespitosu. It inhibits the fibrovascular activity in the pterygium stroma by 
inhibiting DNA synthesis10. This prevents aggressive wound healing, reducing 
pterygium recurrence after bare sclera excision5,11,12. Studies in rabbits revealed 
that after repeated subconjunctival injections of 0.1ml of MMC, the fibroblast 
and vessels disappeared from the conjunctiva and Tenon capsule, and collagen 
fibers decreased with time12. It has been suggested that MMC can reduce 
inflammation but it has not yet been demonstrated in human studies5. 
 Untreated persistent inflammation may lead to a poor surgical outcome6. 
Moreover, it has been demonstrated that the treatment of this inflammation 
improves the final postoperative outcome5. 
 The aim of this study was to compare inflammatory events and graft 
characteristics between those patients that underwent CLAU with and without 
intraoperative MMC at 1 month and 6 months after surgery. 
Materials and Methods 
Human subjects 
This is a prospective, interventional study that included 69 eyes of 69 patients 
with pterygium and was conducted at Terrassa Health Consortium, from 
January 2013 to July 2015. It is a randomized controlled study with masked 
observers. 
Patients with a history of contact lens wear, previous surgery, temporal or 
double-head pterygium, symblepharon, and other conjunctival lesion than 
pterygium were excluded. 
The study was approved by the Terrassa Health Consortium Ethics Committee 
and informed consents were obtained from patients. The research adhered to 
the tenets of the Declaration of Helsinki. 
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Clinical data concerning patient demography; preoperative examination 
including clinical morphology of the lesion (the grade of visibility of episcleral 
vessels) were assessed under biomicroscopy by a single masked 
observer.Thus, pterygia were classified as atrophic when episcleral vessels 
were clearly distinguished, fleshy when they were totally obscured, and 
intermediate when the vessels were distinguished with difficulty as previously 
described7. Postoperative inflammatory events and clinical adverse effect of the 
drug were registered (see below for details). Recurrence assessment, using 
Prabhasawat criteria13, was also carried out 1 month and 6 months after lesion 
excision. 
Procedure 
All surgeries were performed by the same surgeon using bare sclera excision 
under topical anesthesia. The dissection of Tenon’s during the surgery was as 
minimal as possible taking into account the extent of the pterygium. MMC 
0.025% was applied intraoperatively (in 35 eyes out of the 69 eyes) (MMC+) in 
a soaked cellulose sponge to the scleral bed for 5 min followed by a CLAU, 
attached with a interrupted 10 nylon suture with no scleral bites in both groups 
(MMC+; MMC-). After surgery, a bandage contact lens was applied until corneal 
reepithelization was completed and all patients received an identical regimen of 
topical chloramphenicol and dexamethasone eye drops (De Icol, Alcon, BCN-
Spain) 4 times a day for 1 week and tapered off in 1 month’s time. Sutures were 
removed one week after surgery. 
Postoperative Follow-Up 
Comprehensive slit-lamp examinations of the anterior segment were taken at 1 
month and 6 months after surgery in order to determine the presence of 
inflammatory events such as hyperemia, hemorrhage, graft contraction and 
pyogenic granuloma. 
The hyperemia of the graft’s surrounding conjunctiva was graded using the 
clinical classification previously described by Kheirkhah7 (absence: 0; mild: 1; 
moderate: 2 and severe: 3) (Figure 1). Presence of graft contraction was graded 
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1 and established when graft limits were clearly distinguished and showed 
some degree of dehiscence at 4 weeks after surgery. Absence of graft 
contraction was graded 0 and implied a uniform conjunctiva with normal 
appearance. (Figure 2) 
Presence or absence of hemorrhage and pyogenic granuloma (absence: 0; 
presence: 1) were also recorded. 
Data Processing 
Chi2 test was used to assess differences about number of events between 
groups (MMC+ vs MMC-). Fisher's exact test was used to separately analyze 
differences in each inflammatory event. 
Results 
Sixty-nine eye of 69 patients (43 (62.3%) males and 26 (37.7%) females) 
completed the follow up period. Mean age of the patients was 42.4 years (range 
24 to 79 years). Sixty two (90%) eyes had primary pterygium and 7 (10%) eyes 
had recurrent pterygium. 
Thirty-five eyes underwent through CLAU with mitomycin C (group MMC+) and 
thirty-four eyes CLAU without mitomycin C (group MMC-). There were no 
significant differences in age (p=0.268; student t test), sex (p=0.687; Chi2 test), 
race, lesion morphology, lesion area, grade of preoperative hyperemia and 
grade of visibility of episcleral vessels between the groups (Table 1). Surgery 
was uneventful, and secure attachment of the CLAU was obtained in all cases 
at the end of the surgical procedure.  
Inflammatory events at 1 month after pterygium excision 
No clinical drug adverse effects or recurrence cases were recorded at 1 month 
after surgery. Distribution of the number of inflammatory events in each group at 
1 month after surgery is presented in Table 2. Thirty four (50 %) eyes in the 
whole sample showed at least one complication and MMC- group showed 
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significantly higher number of cases with complications (p <0.001; Chi2 test) 
(Table 2). 
The examination revealed clinical significant conjunctival hyperemia 
surrounding the surgical site in 31 (45%) eyes of the whole sample and this 
inflammatory event was significantly lower in the MMC + group (p <0.001; Chi2 
test) (Table 2).  
Graft contraction on the host site was found in 21 of 69 eyes (30%).  This 
clinical feature showed a significantly higher incidence in the MMC- group (p 
<0.001; Chi2 test) (Table 2).   
The persistence of hemorrhages one month postoperatively was registered in 
11 of 69 eyes (16%). Although these hemorrhages were less frequent in the 
MMC+, there were no significant differences between the two groups (p>0.05; 
Chi2 test). Pyogenic granuloma developed at the surgical site in 3 eyes (4 %), 2 
of those granulomas were at the MMC– group (p>0.05). It is worth mentioning 
that the 3 cases which initially presented granuloma resolved with the sub-
conjunctival injection of triamcinolone. 
 
Inflammatory event at 6 months after pterygium excision 
Tendency for recurrences was significantly different between both groups 
(p=0.0001; Fisher’s exact test) at the end of the follow-up period. Thirteen 
(38%) eyes showed recurrence (grade 4 of Prabhasawat criteria12) in MMC- 
and no cases were displayed in MMC+. 
Presence of at least 1 inflammatory event was only seen in 16 (23%) cases, all 
of them in MMC-. Specifically, 15 (44%) eyes showed hyperemia and one (3%) 
eye presented conjunctival hemorrhages. No new cases of pyogenic granuloma 
or graft contraction were seen at this time point in both groups. Statistical 
analysis showed significant tendency to higher number of inflammatory events 
in MMC- (p=0.0001; Fisher’s exact test). Presence of conjunctival hyperemia 
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was the only specific event with significant differences between MMC- and 
MMC+ (p= 0.0001; Fisher’s exact test) at 6 months after surgery. 
Discussion 
The presence of certain degree of conjunctival inflammation is usually regarded 
as a normal wound healing process after many conjunctival procedures14-17. 
However, it has been suggested that the persistence of postoperative 
inflammation might lead to recurrences and unsatisfactory aesthetic outcomes6. 
Factors that may play a role in this postoperative inflammation are mostly 
unknown. 
The results of our study assessed the early effect of the use of intraoperative 
MMC on the postoperative conjunctival inflammation after the CLAU surgery. In 
the present study, the conjunctiva was examined in a follow-up period of 1 
month and 6 months in order to determine the postoperative inflammatory 
degree of each group. It is accepted that postoperative inflammatory responses 
could subside one month after the surgery and many studies5,6 have used this 
time point to compare the effect of different surgical techniques on the 
conjunctival condition.  
Because pterygium morphologic features could affect the surgical outcome5, 
eyes were previously evaluated preoperatively in order to dismiss any condition 
that could have influenced the results. No significant differences in type, clinical 
morphology and preoperative hyperemia of the pterygium were found between 
the groups. In addition, no patients presented clinical recurrence at 1 month 
after surgery. 
Adjuvant techniques like intraoperative MMC, 5 FU, conjunctival autograft, 
amniotic membrane transplantation18, subconjunctival MMC injection11, and 
subconjunctival Ranibizumab have been widely evaluated to assess their role in 
preventing recurrence19, but few studies have been focused on postoperative 
inflammation. 
Keirkhah and associates6 noted that Fibrin Glue produced less postoperative 
inflammation than sutures in those patients with conjunctival autograft surgery 
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(61.5% vs 21.4%, respectively). Later they found less inflammation on those 
eyes treated with conjunctival autograft than the ones treated with amniotic 
membrane transplantation (15 % vs 84.2%, respectively). The results of our 
study complement these findings showing that the use of intraoperative CLAU 
with MMC seems to improve the conjunctival condition after the surgery 
decreasing some inflammatory events. As a consequence of this, we might 
conclude that the effect of the MMC could increase the healing of the CLAU.  
Further assessments with a larger sample size are necessary to confirm this 
fact. 
MMC is an alkylating agent that inhibits cellular division by inhibiting DNA and 
cellular RNA. It prevents the proliferation of underlying fibro-vascular tissue due 
to its anti proliferative effect on fibroblasts20,21, induction of fibroblasts 
apoptosis21 and the regulation of intracellular protein expression on mRNA 
levels22. MMC is also known for its potent antiangiogenic properties and that 
explains the suppression of new blood vessel formation at the wound site by 
MMC.17 
Nevertheless, the effect of MMC on the conjunctival inflammation is not well 
known.  Chang et al12, proved that subconjunctival injection of MMC inhibits 
fibrovascular activity, reducing pterygium vascularization as well. Seet and 
associates16 found that MMC reduces collagen deposition and suppress 
inflammation in glaucoma filtration surgery. Jain and associates23 noticed that 
MMC decreases conjunctival inflammation in eyes with allergic conjunctivitis, 
but no previous works have studied the effect of MMC on pterygium regarding 
conjunctival inflammation after surgery.  
This study presents, for the first time, the positive effect of MMC on the clinical 
conjunctival inflammation after CLAU surgery by comparing the inflammatory 
events between MMC + and MMC- groups. The eyes receiving intraoperative 
MMC seems to have lower number of conjunctival inflammatory events after 
surgery. Our results showed a lower incidence of inflammatory events at 1 
month and 6 months after surgery in MMC+ (28.5% and 0% respectively) that 
those reported by Solomon et al15 (31.5%) 3 month after extensive pterygium 
surgery using amniotic membrane transplantation without MMC, and those by 
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Keirkhah3 and associates (40.7 %) for conjunctival inflammation using amniotic 
membrane transplantation with MMC application at 1 month after surgery. This 
study shows the incidence of inflammatory events is lower not just 1 month after 
the procedure but also after 6 months at MMC+. Although it is not the primary 
aim of our study, results confirm a statistical significant higher incidence of 
recurrences in MMC-. In our opinion, a higher incidence of inflammatory events 
may be related to a higher rate of recurrences. It seems that CLAU with MMC 
could be the better combination not only to reduce recurrences8 but also 
inflammatory events.  
Parallel to lower incidence of postoperative conjunctival inflammation, there was 
lower incidence of pyogenic granuloma after MMC+ compared with MMC- 
(2.9% vs 5.9%, respectively) 1 month after the surgery, although the difference 
was not significant, probably due to the few incidence disclosed. This lesion, 
which is inflammatory, is caused by exuberant healing with fibrovascular 
proliferation24 and it is plausible to think that MMC could minimize the process. 
New studies with a large sample size could be necessaries to corroborate this 
hypothesis. 
Despite of the important role of MMC  in the treatment of the ocular diseases 
such as pterygium11, penfingoid26 and glaucoma27 there are some possible 
complications, related with MMC effect on corneal epithelial healing28and stem 
cell toxicity. Persistent epithelial and endothelial defects and ischemic scleral 
necrosis have been reported after topical use.29 To minimize MMC side effects 
and complications associated it is very important that the drug should be used 
in optimal concentration and exposure, and patients be carefully selected11, 
excluding those with ulcer predisposition, wound healing such as Sjögren 
syndrome, severe keratoconjunctivitis, pre-existing corneal endothelial 
problems or herpes keratitis. 
Future studies with larger sample sizes are required to analyze if MMC also 
reduces incidence of uncommon inflammatory events and to evaluate the role 
of other factors such as age, gender, pterygium morphologic features and 
different surgical techniques in the incidence of such postoperative 
inflammation.  
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In conclusion, eyes receiving intraoperative MMC after CLAU seems to present 
less hyperemia and graft contraction after surgery than those that did not 
receive MMC as an adjuvant factor. Intraoperative MMC could be also 
associated with a lower recurrence rates.  
 
 
 
 
 
 
 
Figure 1. Absence (A) /Presence (B) of graft contraction 1 month after surgery. 
Note in image B the clear visualization of the graft limits and graft dehiscence 
with underlying bare sclera. 
 
 
 
(A) (B) 
13 
 
 
Figure 2. Postoperative conjunctival hyperemia. According to the degree of 
blood vessels injection, inflammation was graded as 0 (no hyperemia; A), grade 
1 (mild B), grade 2 (moderate C) and grade 3 (severe D), in this case with 
presence of diffuse hemorrhage. 
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Preoperative Clinical 
Findings 
MMC + Group MMC - Group p-value 
 
No. % No. % 
 
Type of pterygium 
    
0.480* 
Primary 32 91.4 30 88.2 
 
Recurrent 3 8.6 4 11.8 
 
Pterygium morphology 
    
0.560* 
atrophic 6 17.1 9 26.5 
 
intermediate 19 54.3 18 52.9 
 
fleshy 10 28.6 7 20.6 
 
Race 
    
0.135* 
Caucasian 13 37.1 13 38.2 
 
Hispanic 16 45.7 20 58.8 
 
African 6 17.1 1 2.9 
 
Lesion area (mean ± SD) in 
mm2 
5.4 ± 3.9 
 
5.8 ± 3.6 
 
0.679** 
 
 
Table 1 Preoperative Clinical Findings. * Fisher exact test. **Student t test. SD: 
standard deviation 
 
 
Postoperative Clinical 
Findings 
MMC + Group MMC - Group p-value 
 
No.   % No.   % 
 
Presence of at least one 
complication 
10 28.5  24 70.5  0.001* 
Conjunctival hyperemia 9 25.7 22 64,7 0.001** 
Graft contraction 1 2.9 20 47.1 0.001** 
Conjunctival hemorrhages 4 2.9 7 26.5 0.230** 
Conjunctival granuloma 1 2.9 2 5.9 0.614** 
 
 
Table 2 Postoperative complications after LCAU with and without intraoperative 
MMC application. * Chi2 test. **Fisher exact test.   
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